Kristina Graudenz

Drug–Drug Interaction Potential of Darolutamide: In Vitro and Clinical Studies

Christian Zurth, Mikko Koskinen, Robert E. Fricke et al. · European Journal of Drug Metabolism and Pharmacokinetics · 2019 · 102 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +17

Evaluation of Clinically Relevant Drug–Drug Interactions and Population Pharmacokinetics of Darolutamide in Patients with Nonmetastatic Castration-Resistant Prostate Cancer: Results of Pre-Specified and Post Hoc Analyses of the Phase III ARAMIS Trial

Neal D. Shore, Christian Zurth, Robert E. Fricke et al. · Targeted Oncology · 2019 · 94 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Significant localized reduction in cerebral blood flow (CBF) in regions relevant to cognitive function with enzalutamide (ENZA) compared to darolutamide (DARO) and placebo (PBO) in healthy volunteers.

Steven Williams, Ndaba Mazibuko, Owen O’Daly et al. · Journal of Clinical Oncology · 2020 · 15 citations

Medicine, Neuroscience, Pharmacology +16